Suppr超能文献

替普罗单抗治疗甲状腺眼病后的副作用和不良事件:一项回顾性观察病例系列研究

Side Effects and Adverse Events After Treatment With Teprotumumab for Thyroid Eye Disease: A Retrospective Observational Case Series.

作者信息

Mukit Fabliha A, Manley Andrew, Patel Akash B, Hashemi Marium, Laplant Jacquelyn F, Fleming James C, Fowler Brian T

机构信息

Ophthalmology, Hamilton Eye Institute, Memphis, USA.

Ophthalmology, The University of Tennessee Health Science Center, Memphis, USA.

出版信息

Cureus. 2024 Apr 19;16(4):e58585. doi: 10.7759/cureus.58585. eCollection 2024 Apr.

Abstract

As the use of teprotumumab for thyroid eye disease (TED) becomes more prolific, there remains a scarcity of literature regarding the associated side effects and adverse events of teprotumumab use. The authors present a single-center retrospective, observational case review of TED patients who received at least a single dose of teprotumumab infusion at the oculofacial plastic surgery service between February 2020 and July 2023. The most predominant recollected side effects were fatigue, brittle nails, dry eye symptoms, hair loss, muscle spasms, and dry mouth. Significant adverse events were limited to two cases of a blood clot and a single case of pulmonary embolism. This is the first retrospective study of patient-reported side effects and adverse events experienced by a cohort of teprotumumab users.

摘要

随着替普罗单抗用于治疗甲状腺眼病(TED)的情况越来越普遍,关于使用替普罗单抗的相关副作用和不良事件的文献仍然匮乏。作者对2020年2月至2023年7月期间在眼面部整形手术科室接受至少单剂量替普罗单抗输注的TED患者进行了一项单中心回顾性观察病例分析。最常见的副作用是疲劳、指甲变脆、干眼症状、脱发、肌肉痉挛和口干。严重不良事件仅限于两例血栓和一例肺栓塞。这是第一项关于一组替普罗单抗使用者报告的副作用和不良事件的回顾性研究。

相似文献

2
Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.
Ophthalmology. 2024 Apr;131(4):458-467. doi: 10.1016/j.ophtha.2023.10.018. Epub 2023 Oct 16.
3
Teprotumumab: A Review in Thyroid Eye Disease.
Drugs. 2022 Nov;82(17):1663-1670. doi: 10.1007/s40265-022-01804-1. Epub 2022 Nov 23.
4
Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
Ophthalmology. 2021 Nov;128(11):1627-1651. doi: 10.1016/j.ophtha.2021.04.024. Epub 2021 Apr 28.
5
The Adverse Effects Profile of Teprotumumab.
J Clin Endocrinol Metab. 2023 Aug 18;108(9):e654-e662. doi: 10.1210/clinem/dgad213.
6
Real-World Experience With Teprotumumab in Patients With Dysthyroid Optic Neuropathy.
J Neuroophthalmol. 2024 Mar 1;44(1):74-79. doi: 10.1097/WNO.0000000000001994. Epub 2023 Sep 25.
7
Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.
J Clin Endocrinol Metab. 2023 Dec 21;109(1):25-35. doi: 10.1210/clinem/dgad637.
8
Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression.
Eye (Lond). 2021 Sep;35(9):2607-2612. doi: 10.1038/s41433-020-01297-w. Epub 2020 Nov 21.
9
A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface.
J Neuroophthalmol. 2022 Mar 1;42(1):26-34. doi: 10.1097/WNO.0000000000001515.

本文引用的文献

1
The changing landscape of thyroid eye disease: current clinical advances and future outlook.
Eye (Lond). 2024 Jun;38(8):1425-1437. doi: 10.1038/s41433-024-02967-9. Epub 2024 Feb 19.
2
Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.
Ophthalmology. 2024 Apr;131(4):458-467. doi: 10.1016/j.ophtha.2023.10.018. Epub 2023 Oct 16.
3
Monoclonal antibodies for the treatment of Graves' ophthalmopathy: A systematic review and meta-analysis.
Saudi J Ophthalmol. 2023 May 2;37(2):137-148. doi: 10.4103/sjopt.sjopt_176_22. eCollection 2023 Apr-Jun.
5
Efficacy and Safety of Teprotumumab in Thyroid Eye Disease.
Ther Clin Risk Manag. 2021 Nov 25;17:1219-1230. doi: 10.2147/TCRM.S303057. eCollection 2021.
7
Ototoxicity and Teprotumumab.
Ann Otol Rhinol Laryngol. 2022 Aug;131(8):910-913. doi: 10.1177/00034894211042740. Epub 2021 Aug 27.
8
Teprotumumab and Hearing Loss: Case Series and Proposal for Audiologic Monitoring.
Ophthalmic Plast Reconstr Surg. 2022;38(1):73-78. doi: 10.1097/IOP.0000000000001995.
9
Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease.
BMJ Case Rep. 2021 May 10;14(5):e242153. doi: 10.1136/bcr-2021-242153.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验